Nippon Life Global Investors Americas Inc. Takes Position in Edwards Lifesciences Corporation $EW

Nippon Life Global Investors Americas Inc. purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, HoldingsChannel reports. The firm purchased 51,670 shares of the medical research company’s stock, valued at approximately $4,674,000.

Several other institutional investors also recently added to or reduced their stakes in EW. MV Capital Management Inc. bought a new stake in Edwards Lifesciences during the 4th quarter valued at about $26,000. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences in the 1st quarter worth about $25,000. Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth about $27,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter worth approximately $25,000. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 25,570 shares of company stock worth $2,219,390 over the last 90 days. Company insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on EW. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Citigroup raised their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Truist Financial lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Finally, Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Trading Down 0.1%

NYSE:EW opened at $91.51 on Monday. The firm has a 50-day simple moving average of $88.73 and a 200-day simple moving average of $84.38. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The firm has a market cap of $52.69 billion, a P/E ratio of 52.59, a P/E/G ratio of 2.30 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.